<DOC>
	<DOCNO>NCT00430144</DOCNO>
	<brief_summary>-list item one , The purpose study evaluate overall response rate belotecan ( CKD-602 ) recurrent progressive carcinoma uterine cervix</brief_summary>
	<brief_title>Belotecan ( CKD-602 ) Recurrent Progressive Carcinoma Uterine Cervix</brief_title>
	<detailed_description>- list item one , evaluate toxicity Belotecan - list item two , evaluate duration primary response respond patient - list item three , evaluate time disease progression - list item four , evaluate progression free survival overall survival .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Belotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm , patient recurrent uterine cervical carcinoma unsuitable candidate curative treatment surgery and/or radiotherapy . One follow histologic type Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma Clinically measurable disease Performance status 0 , 1 , 2 ECOG criterion Histology neuroendocrine tumor Patient previously treat topoisomeraseI inhibitor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>